I. AMENDMENT

IN THE CLAIMS

Please amend claims 1-3 and 59 as follows.

B1 Sub C24

1. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence as set forth in SEQ ID NO: 1;

(b) a nucleotide sequence encoding the polypeptide set forth in SEQ ID NO: 2;

(c) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of (a) or (b); and

(e) a nucleotide sequence complementary to any of (a)-(c).

2. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a polypeptide that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the polypeptide set forth in SEQ ID NO: 2, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2;

(b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence as set forth in SEQ ID NO: 1;

(c) a nucleotide sequence of SEQ ID NO: 1; (a); or (b) encoding a polypeptide fragment of at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2;

(d) a nucleotide sequence of SEQ ID NO: 1, or (a)-(c) comprising a fragment of at least about 16 nucleotides;

(e) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(d); and

(f) a nucleotide sequence complementary to any of (a)-(c).

3. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

Cont B1

(a) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2;

(b) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2;

(c) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2;

(d) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 which has a C- and/or N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2;

(e) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 2;

(f) a nucleotide sequence of (a)-(e) comprising a fragment of at least about 16 nucleotides;

(g) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(f); and

(h) a nucleotide sequence complementary to any of (a)-(e).

B2 Amd C25

59. (Amended) A diagnostic reagent comprising a detectably labeled polynucleotide encoding the amino acid sequence set out in SEQ ID NO: 2; or a fragment, variant or homolog thereof including allelic variants and spliced variants thereof.

II. RESTRICTION

This paper is in response to the restriction requirement of December 31, 2001, in which the examiner required restriction to one of the following inventions:

Group I:	Claims 1-8, 10, 11, 46-48 and 59-64 (in part), directed to a DNA of SEQ ID NO:1, a vector containing it, a cell transformed with the same, and a method of use of said cell;
Group II:	Claims 1-8, 10, 11, 46-48 and 59-64 (in part), directed to a DNA of SEQ ID NO: 3, a vector containing it, a cell transformed with the same, and a method of use of said cell;
Group III:	Claims 9, 12-14, 16-18, 40-45, 49, 50 and 58 (in part), directed to a polypeptide of SEQ ID NO: 2 and a method of use thereof;
Group IV:	Claims 9, 12-14, 16-18, 40-45, 49, 50 and 58 (in part), directed to a polypeptide of SEQ ID NO: 4 and a method of use thereof;
Group V:	Claim 15, directed to a polypeptide of SEQ ID NO: 6;
Group VI:	Claims 19-21 and 23-38 (in part), directed to an antibody against a polypeptide of SEQ ID NO: 2 and a method of use thereof;
Group VII:	Claims 19-21 and 23-38 (in part), directed to an antibody against a polypeptide of SEQ ID NO: 4 and a method of use thereof;
Group VIII:	Claims 20, 21 and 23 (in part), directed to an antibody against a polypeptide of SEQ ID NO: 6 and a method of use thereof;
Group IX:	Claims 22 and 39 (in part), directed to a hybridoma producing an antibody against a polypeptide of SEQ ID NO: 2;
Group X:	Claims 22 and 39 (in part), directed to a hybridoma